米氮平治疗抑郁症的临床疗效及安全性

目的:比较米氮平与阿米替林治疗抑郁症的疗效及安全性。方法:63例抑郁症患者随机分为2组,米氮平组32例给米氮平30mg,po,qn;阿米替林组31例采取从小量逐渐加药的方式,d1～d2 25mg,d3～d4 50mg,d5～d6 75mg,d7起100mg,po,bid,2组疗程均为6周。结果:米氮平组6周末显效率84.4％,痊愈率65.6％;阿米 替林组6周末显效率83.9％,痊愈率61.3％。2组疗效差异无显著性(P>0.05)。药物不良反应发生率米氮平明显低于阿米替林。结论:米氮平治疗抑郁症有效,未发现严重不良反应。

Comparative study on the efficacy and safety of mirtazapine and amitriptyline in treatment of depression

Objective: To compare the efficacy and safety of mirtazapine and amitriptyline in treatment of depression. Methods: 63 patients with depression were randomly divided to receive oral mirtazapine 100mg qn( n = 32) ;or oral anitriptyline ( n = 31) in progressively increased doses, namely 25mg in the first and second day, 50mg in the third and forth day, 75mg in the fifth and sixth day, and lOOmg bid in the seventh day and thereafter. The duration of treatment was 6 weeks for both groups. Results: At the end of treatment, the effective and cure rate for mirtazapine group were 84.4% and 65.6% respectively,for amitriptyline group were 83.9% and 61.3% respectively. No significant difference was observed between groups. Conclusion:Mirtazaine is effective in treatment of depression and no severe adverse reactions were observed.